Journal of Ophthalmology · 2010 · 28 citations · 9 references
MedicineOphthalmologySurgeryOcular PharmacologyOphthalmic SurgeryPerioperative PharmacologyCataract ManagementCataract SurgeryMedication Effects On VisionTopical Ophthalmic MedicationsCataract Surgery ComplicationsCausal RelationshipsPerioperative Ocular MedicationsProstaglandin ActivityProstaglandin Analog TherapyProstaglandin AnaloguesProstaglandin InhibitorsProstaglandin Pharmacology
To our knowledge, we are reporting the first case of a 59-year-old man who developed recurrent CME with three separate trials of three different prostaglandin class drugs following uncomplicated phacoemulsification with intraocular lens implantation. Despite multiple reports of individual prostaglandin (PG) analogues being suggested as the cause of CME, there are no recommendations regarding withholding these medications in the perioperative period. Our patient first developed CME OD 4-months post uncomplicated cataract extraction. XALATAN (Latanoprost) had been restarted after surgery and discontinued at onset of CME. While off XALATAN (Latanoprost), the patient's CME resolved, but his IOP rose. The patient was started on LUMIGAN (Bimatoprost) to control the IOP, but within weeks his CME recurred. The patient's CME was again treated and his IOP remained acceptable, but then progressively increased. TRAVATAN (Travoprost) was attempted, but he presented with a third round of CME. Definitive conclusions about causal relationships cannot be made without well-designed, prospective clinical trials addressing this issue.
9
Investigative Ophthalmology and Visual Science
Cathy Frey · 2010 · 3.4K citations
Mechanism of Action of Bimatoprost, Latanoprost, and Travoprost in Healthy Subjects
Kin Sheng Lim, Cherie B. Nau, Megan M. O’Byrne et al. · Ophthalmology · 2008 · 167 citations · Full text